Literature DB >> 20595384

Human equilibrative nucleoside transporter-3 (hENT3) spectrum disorder mutations impair nucleoside transport, protein localization, and stability.

Nayoung Kang1, Ah Hyun Jun, Yangzom Doma Bhutia, Natarajan Kannan, Jashvant D Unadkat, Rajgopal Govindarajan.   

Abstract

Accumulating evidence reveals that sole mutations in hENT3 cause a spectrum of human genetic disorders. Among these include H syndrome, characterized by scleroderma, hyperpigmentation, hypertrichosis, hepatomegaly, cardiac abnormalities and musculoskeletal deformities, pigmented hypertrichotic dermatosis with insulin-dependent diabetes syndrome, characterized by autoantibody-negative diabetes mellitus and skin deformities, familial Rosai-Dorfman disease, characterized by short stature, familial histiocytosis and sinus histiocytosis with massive lymphadenopathy (SHML), characterized by severe tissue infiltration of immune cells and swollen lymph nodes. hENT3 spectrum disorders share a common mutation and share overlapping clinical manifestations that display many intriguing resemblances to mitochondrial and lysosomal disorders. Although earlier studies identify hENT3 as a mitochondrial and a lysosomal nucleoside transporter, the precise connections between hENT3 and the pathophysiology of these disorders remain unresolved. In this study, we performed functional and biochemical characterization of these mutations in hENT3. We report severe reductions/losses of hENT3 nucleoside transport functions of hENT3 syndrome mutants. In addition to transport alterations, we provide evidence for possible loss of hENT3 functions in all H and pigmented hypertrichotic dermatosis with insulin-dependent diabetes syndromes due to either mistrafficking or altered stability of mutant hENT3 proteins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20595384      PMCID: PMC2934698          DOI: 10.1074/jbc.M110.109199

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

Review 1.  Mitochondrial DNA mutations in human disease.

Authors:  S DiMauro; E A Schon
Journal:  Am J Med Genet       Date:  2001

2.  Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli.

Authors:  Yafei Huang; M Joanne Lemieux; Jinmei Song; Manfred Auer; Da-Neng Wang
Journal:  Science       Date:  2003-08-01       Impact factor: 47.728

3.  A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies.

Authors:  Y Goto; I Nonaka; S Horai
Journal:  Nature       Date:  1990-12-13       Impact factor: 49.962

4.  A single glycine mutation in the equilibrative nucleoside transporter gene, hENT1, alters nucleoside transport activity and sensitivity to nitrobenzylthioinosine.

Authors:  Dhruba J SenGupta; Pek Y Lum; Yurong Lai; Elena Shubochkina; Aimee H Bakken; Glenda Schneider; Jashvant D Unadkat
Journal:  Biochemistry       Date:  2002-02-05       Impact factor: 3.162

Review 5.  Mutations of peripheral myelin protein 22 result in defective trafficking through mechanisms which may be common to diseases involving tetraspan membrane proteins.

Authors:  C R Sanders; F Ismail-Beigi; M W McEnery
Journal:  Biochemistry       Date:  2001-08-14       Impact factor: 3.162

Review 6.  The equilibrative nucleoside transporter family, SLC29.

Authors:  Stephen A Baldwin; Paul R Beal; Sylvia Y M Yao; Anne E King; Carol E Cass; James D Young
Journal:  Pflugers Arch       Date:  2003-06-28       Impact factor: 3.657

7.  A splice variant of the SLC28A3 gene encodes a novel human concentrative nucleoside transporter-3 (hCNT3) protein localized in the endoplasmic reticulum.

Authors:  Ekaitz Errasti-Murugarren; Miriam Molina-Arcas; Fco Javier Casado; Marçal Pastor-Anglada
Journal:  FASEB J       Date:  2008-09-30       Impact factor: 5.191

8.  Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease.

Authors:  Neil V Morgan; Mark R Morris; Hakan Cangul; Diane Gleeson; Anna Straatman-Iwanowska; Nicholas Davies; Stephen Keenan; Shanaz Pasha; Fatimah Rahman; Dean Gentle; Maaike P G Vreeswijk; Peter Devilee; Margaret A Knowles; Serdar Ceylaner; Richard C Trembath; Carlos Dalence; Erol Kismet; Vedat Köseoğlu; Hans-Christoph Rossbach; Paul Gissen; David Tannahill; Eamonn R Maher
Journal:  PLoS Genet       Date:  2010-02-05       Impact factor: 5.917

9.  The H syndrome is caused by mutations in the nucleoside transporter hENT3.

Authors:  Vered Molho-Pessach; Israela Lerer; Dvorah Abeliovich; Ziad Agha; Abdulasalam Abu Libdeh; Valentina Broshtilova; Orly Elpeleg; Abraham Zlotogorski
Journal:  Am J Hum Genet       Date:  2008-10       Impact factor: 11.025

10.  SLC29A3 gene is mutated in pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome and interacts with the insulin signaling pathway.

Authors:  Simon T Cliffe; Jamie M Kramer; Khalid Hussain; Joris H Robben; Eiko K de Jong; Arjan P de Brouwer; Esther Nibbeling; Erik-Jan Kamsteeg; Melanie Wong; Julie Prendiville; Chela James; Raja Padidela; Charlie Becknell; Hans van Bokhoven; Peter M T Deen; Raoul C M Hennekam; Robert Lindeman; Annette Schenck; Tony Roscioli; Michael F Buckley
Journal:  Hum Mol Genet       Date:  2009-03-31       Impact factor: 6.150

View more
  28 in total

1.  Inhibition of Transient Receptor Potential Channel Mucolipin-1 (TRPML1) by Lysosomal Adenosine Involved in Severe Combined Immunodeficiency Diseases.

Authors:  Xi Zoë Zhong; Yuanjie Zou; Xue Sun; Gaofeng Dong; Qi Cao; Aditya Pandey; Jan K Rainey; Xiaojuan Zhu; Xian-Ping Dong
Journal:  J Biol Chem       Date:  2017-01-13       Impact factor: 5.157

Review 2.  Equilibrative nucleoside transporters-A review.

Authors:  Rebba C Boswell-Casteel; Franklin A Hays
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2016-10-19       Impact factor: 1.381

3.  The Concise Guide to PHARMACOLOGY 2013/14: transporters.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  A Case of SLC29A3 Spectrum Disorder-Unresponsive to Multiple Immunomodulatory Therapies.

Authors:  Anoop Mistry; David Parry; Bipin Matthews; Philip Laws; Mark Goodfield; Sinisa Savic
Journal:  J Clin Immunol       Date:  2016-05-23       Impact factor: 8.317

5.  Mutation in the SLC29A3 Gene in an Egyptian Patient with H Syndrome: A Case Report and Review of Literature.

Authors:  Hala T El-Bassyouni; Manal M Thomas; Angie M S Tosson
Journal:  J Pediatr Genet       Date:  2019-09-30

6.  Whole-exome sequencing identifies mutations in the nucleoside transporter gene SLC29A3 in dysosteosclerosis, a form of osteopetrosis.

Authors:  Philippe M Campeau; James T Lu; Gautam Sule; Ming-Ming Jiang; Yangjin Bae; Simran Madan; Wolfgang Högler; Nicholas J Shaw; Steven Mumm; Richard A Gibbs; Michael P Whyte; Brendan H Lee
Journal:  Hum Mol Genet       Date:  2012-08-08       Impact factor: 6.150

Review 7.  Purine import into malaria parasites as a target for antimalarial drug development.

Authors:  I J Frame; Roman Deniskin; Avish Arora; Myles H Akabas
Journal:  Ann N Y Acad Sci       Date:  2014-11-25       Impact factor: 5.691

8.  Accelerated coronary atherosclerosis and H syndrome.

Authors:  Ravindranath K Shankarappa; Rajiv Ananthakrishna; Ravi S Math; Sachin Dhareppa Yalagudri; Satish Karur; Ramesh Dwarakaprasad; Manjunath C Nanjappa; Vered Molho-Pessach
Journal:  BMJ Case Rep       Date:  2011-10-04

9.  Molecular determinants of acidic pH-dependent transport of human equilibrative nucleoside transporter 3.

Authors:  Md Fazlur Rahman; Candice Askwith; Rajgopal Govindarajan
Journal:  J Biol Chem       Date:  2017-07-20       Impact factor: 5.157

10.  FUN26 (function unknown now 26) protein from saccharomyces cerevisiae is a broad selectivity, high affinity, nucleoside and nucleobase transporter.

Authors:  Rebba C Boswell-Casteel; Jennifer M Johnson; Kelli D Duggan; Zygy Roe-Žurž; Hannah Schmitz; Carter Burleson; Franklin A Hays
Journal:  J Biol Chem       Date:  2014-07-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.